Abstract
Bloodstream infections (BSI) are a main cause of infectious disease morbidity and mortality world-wide. Early prediction of patients at high risk of poor outcomes of BSI is important for earlier decision making and effective patient stratification. We developed electronic medical record-based machine learning models that predict patient outcomes of BSI. The area under the receiver-operating characteristics curve was 0.82 for a full featured inclusive model, and 0.81 for a compact model using only 25 features. Our models were trained, using electronic medical records that include demographics, blood tests, and the medical and diagnosis history of 7,889 hospitalized patients diagnosed with BSI. Among the implications of this work is implementation of the models as a basis for selective rapid microbiological identification, toward earlier administration of appropriate antibiotic therapy. Additionally, our models may help reduce the development of BSI and its associated adverse health outcomes and complications.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Y.Z. and D.L. are partially supported by the Edmond J. Safra Center for Bioinformatics at Tel-Aviv University. The Shomron lab is partially supported by the Adelis Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study (TLV-0684-18) was approved by the TASMC Institutional Review Board (IRB). All methods were performed in accordance with the IRB policy, guidelines, and regulations. Informed consent was waived by the IRB, as all identifying details of the participants were removed before any computational analysis.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are from TASMC. Access restrictions apply to these data and they are therefore not publicly available. Due to these restrictions, these data can be ac-cessed only by request to TASMC or the authors.
